Optimizing therapeutic antibody function: progress with Fc domain engineering.

Area of Science:

• Biotechnology
• Immunology
• Pharmacology

Background:

• Monoclonal antibody therapeutics have advanced significantly since the 1970s, with chimeric, humanized, and fully human antibodies representing major breakthroughs.
• Despite successes like rituximab and trastuzumab, current antibody therapeutics require enhanced efficacy for optimal patient outcomes.
• Fc-mediated functions, including antibody-dependent cellular cytotoxicity and neonatal Fc receptor-mediated storage, are recognized as key to improving therapeutic antibody performance.

Purpose of the Study:

• This review focuses on recent advancements in Fc engineering to enhance therapeutic antibody functions.
• It explores methods to modulate Fc-mediated activities, aiming to improve clinical efficacy.
• The review highlights the development of third-generation therapeutic antibodies utilizing these engineered Fc regions.

Main Methods:

• Fc engineering strategies are primarily categorized into two approaches.
• These include introducing specific amino acid mutations within the Fc region.
• The second approach involves modifying the Fc-linked oligosaccharide structures.

Main Results:

• Fc engineering can dramatically improve, and in some cases, silence Fc-mediated functions.
• These modifications are designed to optimize antibody-mediated effector functions and pharmacokinetic properties.
• Engineered Fc regions are being incorporated into novel antibody designs for clinical evaluation.

Conclusions:

• Fc engineering represents a critical strategy for developing next-generation therapeutic antibodies.
• The modulation of Fc functions through amino acid or glycosylation changes holds significant promise for improving treatment efficacy.
• Third-generation therapeutic antibodies with engineered Fcs are poised for clinical testing, offering potential for enhanced patient benefits.